Carotid Artery Stenting for Acute Ischemic Stroke Patients after Intravenous Recombinant Tissue Plasminogen Activator Treatment

Ichiro Deguchi¹, Takeshi Hayashi¹, Hiroaki Neki², Fumitaka Yamane², Shoichiro Ishihara², Norio Tanahashi¹ and Masaki Takao¹

Abstract

We herein report three ischemic stroke patients who underwent emergency carotid artery stenting after receiving intravenous tissue plasminogen activator (t-PA) treatment. All patients received antiplatelet medications immediately before stent placement for loading as well as dual antiplatelet therapy after stenting. Under high-dose and dual antiplatelet therapy, none of the three patients showed symptomatic intracranial hemorrhaging. However, one case showed reocclusion of the placed stent after acute thrombosis. As a result, new treatment strategies for the use of antiplatelet agents during emergency stent placement must be developed, particularly for patients who have received intravenous t-PA therapy.

Key words: acute ischemic stroke, recombinant tissue plasminogen activator, carotid artery stenting, antiplatelet therapy

(Intern Med 55: 2869-2872, 2016)  
(DOI: 10.2169/internalmedicine.55.7038)

Introduction

In recent years, the efficacy of endovascular treatment after the administration of intravenous recombinant tissue plasminogen activator (rt-PA) has been demonstrated in several studies (1-5). In fact, the number of patients undergoing endovascular treatment after intravenous rt-PA administration has been increasing. In addition, carotid artery stent placement during endovascular treatment is performed in selected patients in clinical practice. However, strong evidence that supports the effectiveness of emergent stenting treatment is unavailable. Patients who undergo emergency stent placement are recommended to receive antiplatelet therapy to prevent in-stent thrombosis (6), but only a few studies have reported the use of these drugs after carotid artery stenting and intravenous rt-PA administration (7, 8). We herein report our experience with acute antiplatelet therapy in three stroke patients who underwent emergency carotid artery stent placement after intravenous rt-PA administration.

Case Reports

Case 1

A 71-year-old man was brought to our hospital with the chief complaint of acute left hemiplegia. He had a history of hypertension and non-valvular atrial fibrillation (NVAF) and had been receiving oral administration of rivaroxaban (15 mg/day). On arrival, the patient’s National Institute of Health Stroke Scale (NIHSS) score was 14. Head magnetic resonance imaging (MRI) revealed acute cerebral infarction in the right basal ganglia extending to the corona radiata [diffusion-weighted imaging (DWI)-Alberta Stroke Program Early Computed Tomography Score (ASPECTS): 9] (Figure A). Magnetic resonance angiography (MRA) revealed a right internal carotid artery occlusion (Figure B). At 110 minutes after the onset of stroke, rt-PA (time from the last administration of rivaroxaban to rt-PA: 590 minutes) and cerebral endovascular treatment were administered. The

¹Department of Neurology, Saitama Medical University International Medical Center, Japan and ²Department of Endovascular Neurosurgery, Saitama Medical University International Medical Center, Japan

Received for publication December 24, 2015; Accepted for publication February 9, 2016

Correspondence to Dr. Ichiro Deguchi, ideguchi@saitama-med.ac.jp
thrombus was aspirated using the Penumbra® system (Penumbra, Alameda, USA). Although balloon percutaneous transluminal angioplasty (PTA) was performed for the residual right internal carotid artery stenotic lesion, elastic recoil occurred. Therefore, clopidogrel and aspirin were administered at loading doses of 300 and 200 mg, respectively, followed by emergency carotid artery stenting (Carotid WALLSTENT, Boston Scientific, Natick, USA) (Figure C). At 300 minutes after onset (time from the last administration of rivaroxaban to recanalization: 780 minutes), complete recanalization was achieved. After treatment, antiplatelet therapy (clopidogrel 75 mg + aspirin 100 mg) was continued. The patient’s systolic blood pressure (SBP) was maintained at 100 to 130 mmHg by a continuous intravenous infusion of nicardipine. During the follow-up period, the patient remained free of concurrent symptomatic intracranial hemorrhaging (sICH) (Figure D). Although no neurologic changes were noted, follow-up MRA performed on hospital day 4 showed reclosure, likely resulting from in-stent thrombosis (Figure E). On hospital day 35, the patient’s modified Rankin Scale (mRS) score was 2, and he was transferred to another hospital.

Case 2

An 85-year-old man was brought to our hospital with the chief complaints of left hemiplegia and dysarthria. He had a history of hypertension, old cerebral infarction, and NVAF and had been receiving oral administration of aspirin (100 mg/day). On arrival, the patient’s NIHSS score was 14. Head MRI revealed acute cerebral infarction in the right
Carotid artery stent placement for patients who are unresponsive to intravenous rt-PA administration has become a popular treatment in clinical practice. The Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands reported that acute carotid artery stent placement was performed in 12.9% of patients (1). We have performed immediate endovascular treatment after intravenous rt-PA administration for 29 patients in our hospital since September 2012; 23 of these patients had a stroke in the area of anterior circulation. In particular, carotid artery stent placement was performed in three (13%) of 23 patients. The leading complication of carotid artery stent placement after intravenous rt-PA administration is considered to be sICH. In the present study, all three patients received loading doses of antiplatelet drugs during surgery and subsequently received dual antiplatelet therapy, without showing sICH.

In our hospital, the imaging indications for endovascular treatment after intravenous rt-PA administration are based on the MRA-DWI mismatch status (9). In this regard, DWI-ASPECTS ≥6 and a major artery occlusion [internal carotid artery or middle cerebral artery (M1 segment)] were considered to indicate MRA-DWI mismatch and therefore provided support for the use of additional endovascular treatment. Selecting patients according to their MRI findings (e.g., MRA-DWI mismatch) appears to be important to prevent sICH. In our department, the goal of BP control in patients undergoing carotid artery stenting after intravenous rt-PA therapy is set at SBP ≤130 mmHg. Strict BP control is important to prevent hyperperfusion syndrome.

In addition, patients with a vulnerable plaque are at an increased risk for artery-to-artery embolism and acute in-stent thrombosis, as shown in case 1. In this study, one of the patients experienced thrombus formation in the placed stent without any worsening of the neurological symptoms. Symptomatic in-stent thrombosis is rare and is reported to be between 0.04-2% (10, 11). However, because in-stent thrombosis can result in serious consequences, emergency surgical treatment (e.g., PTA, stent-in-stent placement, or thrombectomy) should be considered for such cases.

There is no evidence of emergency stent placement for acute cerebral infarction and there are no clear guidelines for specific medications or loading dosage of antiplatelet agents at the time of stent placement (6). In each of the presented cases, the antiplatelet drug types and doses for both pre-stent loading and after therapy were decided by the attending physician according to the patient’s background variables, including age and pre-onset history of antiplatelet drug use. Therapeutic strategies for the use of antiplatelet drugs in patients undergoing emergency stent placement should be established, with a particular focus on the type and dosing of antiplatelet drugs for patients that have received intravenous rt-PA therapy.

The authors state that they have no Conflict of Interest (COI).
References